A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
Latest Information Update: 18 Nov 2024
Price :
$35 *
At a glance
- Drugs Volenrelaxin (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 12 Nov 2024 Status changed from not yet recruiting to recruiting.
- 30 Sep 2024 New trial record